GHNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Guardant Health, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$157.88−0.72 (-0.45%)
Close on Oct 19, 2026
- Market cap
- $20.98B
- P/E (TTM)
- –
- Dividend yield
- –
Guardant Health, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncology | $219.11M | $204.95M | $189.95M | $184.40M | $158.69M | $150.56M | $145.61M | $141.20M | $130.27M | $125.75M | – | – | 65.4% | +38.1% |
| Biopharma and data | $60.95M | $52.98M | $54.01M | $54.73M | $56.02M | $45.38M | $49.51M | $46.55M | $43.93M | $37.59M | – | – | 18.2% | +8.8% |
| Screening | $52.87M | $41.59M | $35.13M | $24.11M | $14.81M | $5.68M | $4.12M | $1.00M | $0 | $0 | – | – | 15.8% | +256.9% |
| Licensing and other | $2.06M | $2.14M | $2.18M | $1.95M | $2.57M | $1.86M | $2.57M | $2.73M | $3.03M | $5.16M | – | – | 0.6% | -19.8% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $318.04M | $284.63M | $263.55M | $249.44M | $216.68M | $193.61M | $191.59M | $180.11M | $168.12M | $157.35M | $142.62M | $135.74M | 94.9% | +46.8% |
| International | $16.94M | $17.04M | $17.72M | $15.76M | $15.40M | $9.86M | $10.22M | $11.37M | $9.12M | $11.14M | $12.44M | $7.30M | 5.1% | +10.0% |
From the segment and revenue-disaggregation notes of Guardant Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.